Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients

Francesca Bianchi, Massimo Milione, Patrizia Casalini, Giovanni Centonze, Valentino M. Le Noci, Chiara Storti, Spyridon Alexiadis, Mauro Truini, Gabriella Sozzi, Ugo Pastorino, Andrea Balsari, Elda Tagliabue, Lucia Sfondrini

Research output: Contribution to journalArticle

Abstract

Immune and epithelial cells express TLR3, a receptor deputed to respond to microbial signals activating the immune response. The prognostic value of TLR3 in cancer is debated and no data are currently available in NSCLC, for which therapeutic approaches that target the immune system are providing encouraging results. Dissecting the lung immune microenvironment could provide new prognostic markers, especially for early stage NSCLC for which surgery is the only treatment option. In this study we investigated the expression and the prognostic value of TLR3 on both tumor and immune compartments of stage I NSCLCs. In a cohort of 194 NSCLC stage I, TLR3 immunohistochemistry expression on tumor cells predicted a favorable outcome of early stage NSCLC, whereas on the immune cells infiltrating the tumor stroma, TLR3 expression associated with a poor overall survival. Patients with TLR3-positive immune infiltrating cells, but not tumor cells showed a worse prognosis compared with all other patients. The majority of TLR3-expressing immune cells resulted to be macrophages and TLR3 expression associates with PD-1 expression. TLR3 has an opposite prognostic significance when expressed on tumor or immune cells in early stage NCSCL. Analysis of TLR3 in tumor and immune cells can help in identifying high risk stage I patients for which adjuvant treatment would be beneficial.

Original languageEnglish
Article number14288
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Toll-Like Receptor 3
Non-Small Cell Lung Carcinoma
Neoplasms
Immune System
Therapeutics
Epithelial Cells
Immunohistochemistry
Macrophages
Lung
Survival

ASJC Scopus subject areas

  • General

Cite this

Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. / Bianchi, Francesca; Milione, Massimo; Casalini, Patrizia; Centonze, Giovanni; Le Noci, Valentino M.; Storti, Chiara; Alexiadis, Spyridon; Truini, Mauro; Sozzi, Gabriella; Pastorino, Ugo; Balsari, Andrea; Tagliabue, Elda; Sfondrini, Lucia.

In: Scientific Reports, Vol. 9, No. 1, 14288, 01.12.2019.

Research output: Contribution to journalArticle

@article{e1babbc6374e4e1e867b710da02c51d0,
title = "Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients",
abstract = "Immune and epithelial cells express TLR3, a receptor deputed to respond to microbial signals activating the immune response. The prognostic value of TLR3 in cancer is debated and no data are currently available in NSCLC, for which therapeutic approaches that target the immune system are providing encouraging results. Dissecting the lung immune microenvironment could provide new prognostic markers, especially for early stage NSCLC for which surgery is the only treatment option. In this study we investigated the expression and the prognostic value of TLR3 on both tumor and immune compartments of stage I NSCLCs. In a cohort of 194 NSCLC stage I, TLR3 immunohistochemistry expression on tumor cells predicted a favorable outcome of early stage NSCLC, whereas on the immune cells infiltrating the tumor stroma, TLR3 expression associated with a poor overall survival. Patients with TLR3-positive immune infiltrating cells, but not tumor cells showed a worse prognosis compared with all other patients. The majority of TLR3-expressing immune cells resulted to be macrophages and TLR3 expression associates with PD-1 expression. TLR3 has an opposite prognostic significance when expressed on tumor or immune cells in early stage NCSCL. Analysis of TLR3 in tumor and immune cells can help in identifying high risk stage I patients for which adjuvant treatment would be beneficial.",
author = "Francesca Bianchi and Massimo Milione and Patrizia Casalini and Giovanni Centonze and {Le Noci}, {Valentino M.} and Chiara Storti and Spyridon Alexiadis and Mauro Truini and Gabriella Sozzi and Ugo Pastorino and Andrea Balsari and Elda Tagliabue and Lucia Sfondrini",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-50756-2",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients

AU - Bianchi, Francesca

AU - Milione, Massimo

AU - Casalini, Patrizia

AU - Centonze, Giovanni

AU - Le Noci, Valentino M.

AU - Storti, Chiara

AU - Alexiadis, Spyridon

AU - Truini, Mauro

AU - Sozzi, Gabriella

AU - Pastorino, Ugo

AU - Balsari, Andrea

AU - Tagliabue, Elda

AU - Sfondrini, Lucia

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Immune and epithelial cells express TLR3, a receptor deputed to respond to microbial signals activating the immune response. The prognostic value of TLR3 in cancer is debated and no data are currently available in NSCLC, for which therapeutic approaches that target the immune system are providing encouraging results. Dissecting the lung immune microenvironment could provide new prognostic markers, especially for early stage NSCLC for which surgery is the only treatment option. In this study we investigated the expression and the prognostic value of TLR3 on both tumor and immune compartments of stage I NSCLCs. In a cohort of 194 NSCLC stage I, TLR3 immunohistochemistry expression on tumor cells predicted a favorable outcome of early stage NSCLC, whereas on the immune cells infiltrating the tumor stroma, TLR3 expression associated with a poor overall survival. Patients with TLR3-positive immune infiltrating cells, but not tumor cells showed a worse prognosis compared with all other patients. The majority of TLR3-expressing immune cells resulted to be macrophages and TLR3 expression associates with PD-1 expression. TLR3 has an opposite prognostic significance when expressed on tumor or immune cells in early stage NCSCL. Analysis of TLR3 in tumor and immune cells can help in identifying high risk stage I patients for which adjuvant treatment would be beneficial.

AB - Immune and epithelial cells express TLR3, a receptor deputed to respond to microbial signals activating the immune response. The prognostic value of TLR3 in cancer is debated and no data are currently available in NSCLC, for which therapeutic approaches that target the immune system are providing encouraging results. Dissecting the lung immune microenvironment could provide new prognostic markers, especially for early stage NSCLC for which surgery is the only treatment option. In this study we investigated the expression and the prognostic value of TLR3 on both tumor and immune compartments of stage I NSCLCs. In a cohort of 194 NSCLC stage I, TLR3 immunohistochemistry expression on tumor cells predicted a favorable outcome of early stage NSCLC, whereas on the immune cells infiltrating the tumor stroma, TLR3 expression associated with a poor overall survival. Patients with TLR3-positive immune infiltrating cells, but not tumor cells showed a worse prognosis compared with all other patients. The majority of TLR3-expressing immune cells resulted to be macrophages and TLR3 expression associates with PD-1 expression. TLR3 has an opposite prognostic significance when expressed on tumor or immune cells in early stage NCSCL. Analysis of TLR3 in tumor and immune cells can help in identifying high risk stage I patients for which adjuvant treatment would be beneficial.

UR - http://www.scopus.com/inward/record.url?scp=85072931400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072931400&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-50756-2

DO - 10.1038/s41598-019-50756-2

M3 - Article

C2 - 31582772

AN - SCOPUS:85072931400

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 14288

ER -